COVID-19 in a Neuroimmunological Outpatient Cohort: The Bernese Experience
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Patient Cohort
3.2. COVID-19 Course
3.3. Influence of COVID-19 on Underlying Disease
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Louapre, C.; Collongues, N.; Stankoff, B.; Giannesini, C.; Papeix, C.; Bensa, C.; Deschamps, R.; Créange, A.; Wahab, A.; Pelletier, J.; et al. Clinical Characteristics and Outcomes in Patients with Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020, 77, 1079–1088. [Google Scholar] [CrossRef] [PubMed]
- Sormani, M.P.; Rossi, N.D.; Schiavetti, I.; Carmisciano, L.; Cordioli, C.; Moiola, L.; Radaelli, M.; Immovilli, P.; Capobianco, M.; Trojano, M.; et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann. Neurol. 2021, 89, 780–789. [Google Scholar] [CrossRef] [PubMed]
- Salter, A.; Fox, R.J.; Newsome, S.D.; Halper, J.; Li, D.K.B.; Kanellis, P.; Costello, K.; Bebo, B.; Rammohan, K.; Cutter, G.R.; et al. Outcomes and Risk Factors Associated with SARS-CoV-2 Infection in a North American Registry of Patients with Multiple Sclerosis. JAMA Neurol. 2021, 78, 699–708. [Google Scholar] [CrossRef] [PubMed]
- Solé, G.; Mathis, S.; Friedman, D.; Salort-Campana, E.; Tard, C.; Bouhour, F.; Magot, A.; Annane, D.; Clair, B.; Masson, G.L.; et al. Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis. Neurology 2021, 96, e2109–e2120. [Google Scholar] [CrossRef] [PubMed]
- Louapre, C.; Maillart, E.; Papeix, C.; Zeidan, S.; Biotti, D.; Lepine, Z.; Wahab, A.; Zedet, M.; Labauge, P.; Tilikete, C.; et al. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. Eur. J. Neurol. 2021, 28, 3461–3466. [Google Scholar] [CrossRef] [PubMed]
- Pistor, M.; Hoepner, A.; Lin, Y.; Jung, S.; Bassetti, C.L.; Chan, A.; Salmen, A.; Hoepner, R. Immunotherapies and COVID-19 mortality: A multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System. Ann. Rheum. Dis. 2021, 80, 1633–1635. [Google Scholar] [CrossRef] [PubMed]
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID)—Emerging Infections Task Force (EITaF) Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS). Available online: https://leoss.net/ (accessed on 2 August 2021).
- EAN. The EAN NEuro-COVID ReGistrY (ENERGY). Available online: https://www.ean.org/research/registries-surveys/neuro-covid-registry (accessed on 2 August 2021).
- Rüthrich, M.M.; Giessen-Jung, C.; Borgmann, S.; Classen, A.Y.; Dolff, S.; Grüner, B.; Hanses, F.; Isberner, N.; Köhler, P.; Lanznaster, J.; et al. COVID-19 in cancer patients: Clinical characteristics and outcome—An analysis of the LEOSS registry. Ann. Hematol. 2021, 100, 383–393. [Google Scholar] [CrossRef] [PubMed]
- Huber, M.K.; Raichle, C.; Lingor, P.; Synofzik, M.; Borgmann, S.; Erber, J.; Tometten, L.; Rimili, W.; Dolff, S.; Wille, K.; et al. Outcomes of SARS-CoV-2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort. Mov. Disord. 2021, 36, 791–793. [Google Scholar] [CrossRef] [PubMed]
- Friedli, C.; Diem, L.; Hammer, H.; Kamber, N.; Suter-riniker, F.; Leib, S.; Chan, A.; Hirzel, C.; Hoepner, R.; Salmen, A. Negative SARS-CoV-2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies. Ther. Adv. Neurol. Disord. 2021, 14, 17562864211016641. [Google Scholar] [CrossRef] [PubMed]
- Ritchie, H.; Ortiz-Ospina, E.; Beltekian, D.; Mathieu, E.; Hassel, J.; Macdonald, B.; Giattino, C.; Appel, C.; Rodés-Guiro, L.; Roser, M. Our World in Data-COVID Cases-Switzerland. Available online: https://ourworldindata.org/coronavirus/country/switzerland (accessed on 2 August 2021).
- Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; et al. Remdesivir for the Treatment of COVID-19—Final Report. N. Engl. J. Med. 2020, 383, 1813–1826. [Google Scholar] [CrossRef] [PubMed]
- Group, R.C. Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021, 384, 693–704. [Google Scholar] [CrossRef]
- Collard, D.; Nurmohamed, N.S.; Kaiser, Y.; Reeskamp, L.F.; Dormans, T.; Moeniralam, H.; Simsek, S.; Douma, R.; Eerens, A.; Reidinga, A.C.; et al. Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: A prospective cohort study. BMJ Open 2021, 11, e045482. [Google Scholar] [CrossRef] [PubMed]
- Strangfeld, A.; Schäfer, M.; Gianfrancesco, M.A.; Lawson-Tovey, S.; Liew, J.W.; Ljung, L.; Mateus, E.F.; Richez, C.; Santos, M.J.; Schmajuk, G.; et al. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2021, 80, 930–942. [Google Scholar] [CrossRef] [PubMed]
- Sibley, W.; Bamford, C.; Clark, K. Clinical viral infections and multiple sclerosis. Lancet 1985, 325, 1313–1315. [Google Scholar] [CrossRef]
- Correale, J.; Fiol, M.; Gilmore, W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006, 67, 652–659. [Google Scholar] [CrossRef]
- Diem, L.; Friedli, C.; Chan, A.; Salmen, A.; Hoepner, R. Vaccine Hesitancy in Patients With Multiple Sclerosis Preparing for the SARS-CoV-2 Vaccination Challenge. Neurol. Neuroimmunol. Neuroinflamm. 2021, 8, e991. [Google Scholar] [CrossRef] [PubMed]
- Hall, V.G.; Ferreira, V.H.; Ku, T.; Ierukki, M.; Majchrzak-Kita, B.; Chaparro, C.; Selzner, N.; Schiff, J.; McDonald, M.; Tomlinson, G.; et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N. Engl. J. Med. 2021, 385, 1244–1246. [Google Scholar] [CrossRef] [PubMed]
- Weinreich, D.M.; Sivapalasingam, S.; Norton, T.; Ali, S.; Pharm, D.; Gao, H.; Ph, D.; Bhore, R.; Ph, D.; Xiao, J.; et al. REGEN-COV Antibody Cocktail Clinical Outcomes Study in COVID-19 Outpatients. N. Engl. J. Med. 2021, 385, e81. [Google Scholar] [CrossRef] [PubMed]
Category | Subcategory | n |
---|---|---|
Sex | Male | 7/24 |
Female | 17/24 | |
Age | Mean 45.2 (Range: 25–67, 95% CI: 40.2–50.3) | |
Diagnosis | MS | 19/24 |
RRMS | 17/19 | |
SPMS | 1/19 | |
PPMS | 1/19 | |
MG | 2/24 | |
NMOSD | 1/24 | |
Neuro-Behçet’s Disease | 1/24 | |
PERM | 1/24 | |
Disability Status (MS- and NMOSD patients) | Mean EDSS 2.4 (Range: 0–7.0, 95% CI 1.3–3.5) | |
Immunotherapy | No immunotherapy | 4/24 |
Azathioprine | 2/24 | |
Prednisolone 1 | 2/24 | |
Dimethyl Fumarate | 2/24 | |
IFN-Beta | 1/24 | |
IVIG | 1/24 | |
Fingolimod | 4/24 | |
Natalizumab | 1/24 | |
Ocrelizumab | 5/24 | |
Ozanimod | 1/24 | |
Rituximab | 2/24 | |
Cardiovascular Risk Factors 2 | 11/24 |
Category | Subcategory | n |
---|---|---|
Symptoms | General condition deterioration | 18/24 |
Fever | 14/24 | |
Dyspnea | 3/24 | |
Anosmia | 7/24 | |
Pneumonia | 2/24 | |
ARDS | 2/24 | |
Death | 0/24 | |
Care Setting | Outpatient | 18/24 |
Inpatient | 4/24 | |
ICU | 2/24 | |
COVID-19 treatment | Remdesivir and Dexamethasone | 2/24 |
Dexamethasone | 3/24 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pistor, M.; Salmen, A.; Chan, A.; Hoepner, R. COVID-19 in a Neuroimmunological Outpatient Cohort: The Bernese Experience. Clin. Transl. Neurosci. 2022, 6, 6. https://doi.org/10.3390/ctn6010006
Pistor M, Salmen A, Chan A, Hoepner R. COVID-19 in a Neuroimmunological Outpatient Cohort: The Bernese Experience. Clinical and Translational Neuroscience. 2022; 6(1):6. https://doi.org/10.3390/ctn6010006
Chicago/Turabian StylePistor, Maximilian, Anke Salmen, Andrew Chan, and Robert Hoepner. 2022. "COVID-19 in a Neuroimmunological Outpatient Cohort: The Bernese Experience" Clinical and Translational Neuroscience 6, no. 1: 6. https://doi.org/10.3390/ctn6010006